[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fh8sfsn16Wa60cz1ZkqDYTVLXq7sx4aswx038kT05tpQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":8,"nonDrugCount":10,"topConditions":11,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Gachon University Gil Medical Center",[4],90,false,2,12251,38,[12,15,18,21,24,26,28,30],{"name":13,"count":14},"Hypercholesterolemia",7,{"name":16,"count":17},"Allergic Rhinitis",5,{"name":19,"count":20},"Hypertriglyceridemia",4,{"name":22,"count":23},"Stomach Neoplasm",3,{"name":25,"count":23},"Cerebral Ischemia",{"name":27,"count":23},"Hypertension",{"name":29,"count":8},"Radius Fractures",{"name":31,"count":8},"Hypoxia",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT07147114","Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)","2027-09-30","Combination therapy",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,75,93,128,162,183,209,227,252,274,299,323,349,367,385,409,435,453,477,536,565,594,612,636,660,683,708,733,758,776,800,825,843,868,891,915,939,965,992,1010,1028,1086,1118,1149,1178,1196,1214,1232,1257,1275,1293,1311,1329,1353,1378,1401,1424,1446,1471,1489,1514,1532,1550],{"intervention":37,"totalTrials":47,"cells":48},1,{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":73},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":47,"soonestReadout":36},[60],{"nctId":34,"briefTitle":35,"status":61,"phases":62,"primaryCompletion":36,"completion":36,"start":63,"enrollment":64,"conditions":65,"interventions":71},"RECRUITING",[43],"2025-11-24",64,[66,67,68,69,70],"Combined Pre- and Post-capillary Pulmonary Hypertension","CpcPH","HFmrEF","HFpEF","Group 2 Pulmonary Hypertension",[37,72],"Monotherapy",{"trials":74,"activeCount":51},[],{"intervention":72,"totalTrials":47,"cells":76},{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":91},{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[],{"trials":84,"activeCount":51},[],{"trials":86,"activeCount":47,"soonestReadout":36},[87],{"nctId":34,"briefTitle":35,"status":61,"phases":88,"primaryCompletion":36,"completion":36,"start":63,"enrollment":64,"conditions":89,"interventions":90},[43],[66,67,68,69,70],[37,72],{"trials":92,"activeCount":51},[],{"intervention":94,"totalTrials":8,"cells":95},"fenofibrate",{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":126},{"trials":97,"activeCount":51},[],{"trials":99,"activeCount":51},[],{"trials":101,"activeCount":51},[],{"trials":103,"activeCount":51},[],{"trials":105,"activeCount":51},[106,118],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT01666041","Vascular and Metabolic Effects of Fenofibrate\u002FOmega vs Fenofibrate","COMPLETED",[43],"2013-02","2013-07","2012-01",120,[19],[117,94],"fenofibrate\u002Fomega",{"nctId":119,"briefTitle":120,"status":109,"phases":121,"completion":122,"start":123,"conditions":124,"interventions":125},"NCT00745407","Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients",[43],"2008-08","2005-01",[19],[94],{"trials":127,"activeCount":51},[],{"intervention":129,"totalTrials":8,"cells":130},"vytorin",{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":160},{"trials":132,"activeCount":51},[],{"trials":134,"activeCount":51},[],{"trials":136,"activeCount":51},[],{"trials":138,"activeCount":51},[],{"trials":140,"activeCount":51},[141,151],{"nctId":142,"briefTitle":143,"status":109,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":150},"NCT01660945","Vascular and Metabolic Effects of Vytorin",[43],"2012-07","2012-11","2011-07",204,[13],[129],{"nctId":152,"briefTitle":153,"status":109,"phases":154,"primaryCompletion":155,"completion":146,"start":156,"enrollment":148,"conditions":157,"interventions":158},"NCT01666067","Vascular and Metabolic Effects of Vytorin vs Simvastatin",[43],"2012-10","2011-11",[13],[129,159],"simvastatin",{"trials":161,"activeCount":51},[],{"intervention":163,"totalTrials":47,"cells":164},"statin",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":181},{"trials":166,"activeCount":51},[],{"trials":168,"activeCount":51},[],{"trials":170,"activeCount":51},[],{"trials":172,"activeCount":51},[],{"trials":174,"activeCount":51},[175],{"nctId":176,"briefTitle":177,"status":109,"phases":178,"completion":122,"start":123,"conditions":179,"interventions":180},"NCT00745836","Effects of Atorvastatin on Adiponectin Levels and Insulin Sensitivity In Hypercholesterolemic Patients",[43],[13],[163],{"trials":182,"activeCount":51},[],{"intervention":184,"totalTrials":47,"cells":185},"Pitavastatin",{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":194,"NA":207},{"trials":187,"activeCount":51},[],{"trials":189,"activeCount":51},[],{"trials":191,"activeCount":51},[],{"trials":193,"activeCount":51},[],{"trials":195,"activeCount":51},[196],{"nctId":197,"briefTitle":198,"status":199,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT01871792","Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction","UNKNOWN",[43],"2014-02","2013-06",404,[205],"Contrast-induced Nephropathy",[184],{"trials":208,"activeCount":51},[],{"intervention":117,"totalTrials":47,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":225},{"trials":212,"activeCount":51},[],{"trials":214,"activeCount":51},[],{"trials":216,"activeCount":51},[],{"trials":218,"activeCount":51},[],{"trials":220,"activeCount":51},[221],{"nctId":107,"briefTitle":108,"status":109,"phases":222,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":223,"interventions":224},[43],[19],[117,94],{"trials":226,"activeCount":51},[],{"intervention":228,"totalTrials":47,"cells":229},"rosuvastatin",{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":250},{"trials":231,"activeCount":51},[],{"trials":233,"activeCount":51},[],{"trials":235,"activeCount":51},[],{"trials":237,"activeCount":51},[],{"trials":239,"activeCount":51},[240],{"nctId":241,"briefTitle":242,"status":109,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":249},"NCT01660919","Vascular and Metabolic Effects of Rosuvastatin",[43],"2013-01","2013-12","2011-10",160,[13],[228],{"trials":251,"activeCount":51},[],{"intervention":253,"totalTrials":47,"cells":254},"statin, amlodipine",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":272},{"trials":256,"activeCount":51},[],{"trials":258,"activeCount":51},[],{"trials":260,"activeCount":51},[],{"trials":262,"activeCount":51},[],{"trials":264,"activeCount":51},[265],{"nctId":266,"briefTitle":267,"status":109,"phases":268,"completion":122,"start":269,"conditions":270,"interventions":271},"NCT00741078","Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension",[43],"2004-12",[27],[253],{"trials":273,"activeCount":51},[],{"intervention":275,"totalTrials":47,"cells":276},"omega",{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":283,"PHASE4":285,"NA":297},{"trials":278,"activeCount":51},[],{"trials":280,"activeCount":51},[],{"trials":282,"activeCount":51},[],{"trials":284,"activeCount":51},[],{"trials":286,"activeCount":51},[287],{"nctId":288,"briefTitle":289,"status":109,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT01660932","Vascular and Metabolic Effects of Omega-3 Fatty Acids",[43],"2012-08","2012-09","2011-03",176,[19],[275],{"trials":298,"activeCount":51},[],{"intervention":300,"totalTrials":47,"cells":301},"fenofibrate, fatty acid, placebo",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":321},{"trials":303,"activeCount":51},[],{"trials":305,"activeCount":51},[],{"trials":307,"activeCount":51},[],{"trials":309,"activeCount":51},[],{"trials":311,"activeCount":51},[312],{"nctId":313,"briefTitle":314,"status":109,"phases":315,"primaryCompletion":316,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":320},"NCT01003847","Differential Metabolic Effects of Fenofibrate and Fatty Acid",[43],"2010-09","2009-11",150,[19],[300],{"trials":322,"activeCount":51},[],{"intervention":324,"totalTrials":47,"cells":325},"Rosuvastatin and fenofibrate",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":347},{"trials":327,"activeCount":51},[],{"trials":329,"activeCount":51},[],{"trials":331,"activeCount":51},[],{"trials":333,"activeCount":51},[],{"trials":335,"activeCount":51},[336],{"nctId":337,"briefTitle":338,"status":199,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT02232360","Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone",[43],"2020-12","2014-01",106,[344],"Coronary Artery Disease",[324,346],"Rosuvastatin alone",{"trials":348,"activeCount":51},[],{"intervention":346,"totalTrials":47,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":365},{"trials":352,"activeCount":51},[],{"trials":354,"activeCount":51},[],{"trials":356,"activeCount":51},[],{"trials":358,"activeCount":51},[],{"trials":360,"activeCount":51},[361],{"nctId":337,"briefTitle":338,"status":199,"phases":362,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":363,"interventions":364},[43],[344],[324,346],{"trials":366,"activeCount":51},[],{"intervention":159,"totalTrials":47,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":383},{"trials":370,"activeCount":51},[],{"trials":372,"activeCount":51},[],{"trials":374,"activeCount":51},[],{"trials":376,"activeCount":51},[],{"trials":378,"activeCount":51},[379],{"nctId":152,"briefTitle":153,"status":109,"phases":380,"primaryCompletion":155,"completion":146,"start":156,"enrollment":148,"conditions":381,"interventions":382},[43],[13],[129,159],{"trials":384,"activeCount":51},[],{"intervention":386,"totalTrials":47,"cells":387},"pravastatin, valsartan, pravastatin+valsartan",{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":407},{"trials":389,"activeCount":51},[],{"trials":391,"activeCount":51},[],{"trials":393,"activeCount":51},[],{"trials":395,"activeCount":51},[],{"trials":397,"activeCount":51},[398],{"nctId":399,"briefTitle":400,"status":109,"phases":401,"primaryCompletion":402,"completion":402,"start":317,"enrollment":403,"conditions":404,"interventions":406},"NCT01004237","Additive Effects of Pravastatin and Valsartan",[43],"2012-04",52,[27,405],"High Cholesterol",[386],{"trials":408,"activeCount":51},[],{"intervention":410,"totalTrials":47,"cells":411},"Carvedilol",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":433},{"trials":413,"activeCount":51},[],{"trials":415,"activeCount":51},[],{"trials":417,"activeCount":51},[],{"trials":419,"activeCount":51},[],{"trials":421,"activeCount":51},[422],{"nctId":423,"briefTitle":424,"status":109,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":431},"NCT02547597","Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris",[43],"2013-08","2011-04",99,[430],"Stable Angina Pectoris",[410,432],"Atenolol",{"trials":434,"activeCount":51},[],{"intervention":432,"totalTrials":47,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":451},{"trials":438,"activeCount":51},[],{"trials":440,"activeCount":51},[],{"trials":442,"activeCount":51},[],{"trials":444,"activeCount":51},[],{"trials":446,"activeCount":51},[447],{"nctId":423,"briefTitle":424,"status":109,"phases":448,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":449,"interventions":450},[43],[430],[410,432],{"trials":452,"activeCount":51},[],{"intervention":454,"totalTrials":47,"cells":455},"ramipril, candesartan",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":475},{"trials":457,"activeCount":51},[],{"trials":459,"activeCount":51},[],{"trials":461,"activeCount":51},[],{"trials":463,"activeCount":51},[],{"trials":465,"activeCount":51},[466],{"nctId":467,"briefTitle":468,"status":109,"phases":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT00356395","Safety and Effects of Ramipril Combined With Candesartan",[43],"2006-03","2003-08",40,[27],[454],{"trials":476,"activeCount":51},[],{"intervention":478,"totalTrials":20,"cells":479},"Irinotecan",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":481,"activeCount":51},[],{"trials":483,"activeCount":51},[],{"trials":485,"activeCount":51},[486,497,509,521],{"nctId":487,"briefTitle":488,"status":199,"phases":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":495},"NCT00319800","Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC",[41],"2007-03","2006-02",50,[494],"Non-Small Cell Lung Cancer",[496,478],"Gefitinib",{"nctId":498,"briefTitle":499,"status":199,"phases":500,"completion":501,"start":502,"enrollment":492,"conditions":503,"interventions":506},"NCT00509964","Second-Line Irinotecan vs. ILF for AGC",[41],"2007-07","2007-05",[22,504,505],"Metastatic","Second-Line",[507,508],"irinotecan","ILF",{"nctId":510,"briefTitle":511,"status":512,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":520},"NCT00320320","Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer","TERMINATED",[41],"2007-04","2005-04",72,[518,519],"Colorectal Neoplasms","Metastases",[478],{"nctId":522,"briefTitle":523,"status":199,"phases":524,"completion":490,"start":525,"enrollment":526,"conditions":527,"interventions":528},"NCT00320294","ILF With\u002FWithout Cisplatin for Advanced Gastric Cancer",[41],"2005-02",86,[22],[507,529],"cisplatin",{"trials":531,"activeCount":51},[],{"trials":533,"activeCount":51},[],{"trials":535,"activeCount":51},[],{"intervention":496,"totalTrials":8,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":539,"activeCount":51},[],{"trials":541,"activeCount":51},[],{"trials":543,"activeCount":51},[544,548],{"nctId":487,"briefTitle":488,"status":199,"phases":545,"completion":490,"start":491,"enrollment":492,"conditions":546,"interventions":547},[41],[494],[496,478],{"nctId":549,"briefTitle":550,"status":109,"phases":551,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":557},"NCT01783834","Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients",[41],"2014-06","2008-02",95,[556],"Previous Treated Metastatic Non-small Cell Lung Cancer",[496,558],"Pemetrexed",{"trials":560,"activeCount":51},[],{"trials":562,"activeCount":51},[],{"trials":564,"activeCount":51},[],{"intervention":566,"totalTrials":8,"cells":567},"Cisplatin",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":569,"activeCount":51},[],{"trials":571,"activeCount":51},[],{"trials":573,"activeCount":51},[574,584],{"nctId":575,"briefTitle":576,"status":199,"phases":577,"completion":578,"start":501,"enrollment":6,"conditions":579,"interventions":582},"NCT00510107","Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC",[41],"2009-07",[22,580,581],"Stage IV","Recurrent",[583,566],"oxaliplatin",{"nctId":522,"briefTitle":523,"status":199,"phases":585,"completion":490,"start":525,"enrollment":526,"conditions":586,"interventions":587},[41],[22],[507,529],{"trials":589,"activeCount":51},[],{"trials":591,"activeCount":51},[],{"trials":593,"activeCount":51},[],{"intervention":508,"totalTrials":47,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":597,"activeCount":51},[],{"trials":599,"activeCount":51},[],{"trials":601,"activeCount":51},[602],{"nctId":498,"briefTitle":499,"status":199,"phases":603,"completion":501,"start":502,"enrollment":492,"conditions":604,"interventions":605},[41],[22,504,505],[507,508],{"trials":607,"activeCount":51},[],{"trials":609,"activeCount":51},[],{"trials":611,"activeCount":51},[],{"intervention":613,"totalTrials":47,"cells":614},"Metformin",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":616,"activeCount":51},[],{"trials":618,"activeCount":51},[],{"trials":620,"activeCount":51},[621],{"nctId":622,"briefTitle":623,"status":512,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":8,"conditions":627,"interventions":629},"NCT01926769","A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer",[41],"2014-12","2012-02",[628],"Previously Treated Advanced Colorectal Cancer",[613],{"trials":631,"activeCount":51},[],{"trials":633,"activeCount":51},[],{"trials":635,"activeCount":51},[],{"intervention":637,"totalTrials":47,"cells":638},"Genexol-PM",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":640,"activeCount":51},[],{"trials":642,"activeCount":51},[],{"trials":644,"activeCount":51},[645],{"nctId":646,"briefTitle":647,"status":512,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":17,"conditions":651,"interventions":653},"NCT03008512","A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib",[41],"2021-02","2016-10",[652],"Carcinoma, Hepatocellular",[637],{"trials":655,"activeCount":51},[],{"trials":657,"activeCount":51},[],{"trials":659,"activeCount":51},[],{"intervention":661,"totalTrials":47,"cells":662},"oxycodone fentanyl",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":664,"activeCount":51},[],{"trials":666,"activeCount":51},[],{"trials":668,"activeCount":51},[669],{"nctId":670,"briefTitle":671,"status":109,"phases":672,"completion":514,"start":491,"enrollment":673,"conditions":674,"interventions":676},"NCT00478101","Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain",[41],2006,[675],"Advanced Solid Cancers",[661],{"trials":678,"activeCount":51},[],{"trials":680,"activeCount":51},[],{"trials":682,"activeCount":51},[],{"intervention":684,"totalTrials":47,"cells":685},"topotecan",{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":702,"PHASE4":704,"NA":706},{"trials":687,"activeCount":51},[],{"trials":689,"activeCount":51},[],{"trials":691,"activeCount":51},[692],{"nctId":693,"briefTitle":694,"status":199,"phases":695,"completion":696,"start":697,"conditions":698,"interventions":701},"NCT00502762","Topotecan for Irinotecan-Refractory SCLC",[41],"2007-08","2004-09",[699,700],"Lung Cancer","Refractory to Chemotherapy",[684],{"trials":703,"activeCount":51},[],{"trials":705,"activeCount":51},[],{"trials":707,"activeCount":51},[],{"intervention":709,"totalTrials":47,"cells":710},"Docetaxel",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":712,"activeCount":51},[],{"trials":714,"activeCount":51},[],{"trials":716,"activeCount":51},[717],{"nctId":718,"briefTitle":719,"status":109,"phases":720,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":726},"NCT00319514","Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC",[41],"2006-10","2004-04",78,[725],"Advanced Non-Small Cell Lung Cancer",[709],{"trials":728,"activeCount":51},[],{"trials":730,"activeCount":51},[],{"trials":732,"activeCount":51},[],{"intervention":734,"totalTrials":47,"cells":735},"Avelumab and Gemcitabine",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":737,"activeCount":51},[],{"trials":739,"activeCount":51},[],{"trials":741,"activeCount":51},[742],{"nctId":743,"briefTitle":744,"status":199,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"enrollment":10,"conditions":749,"interventions":751},"NCT03536780","Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment",[41],"2021-12-31","2022-12-31","2018-10-01",[750],"Leiomyosarcoma Metastatic",[734],{"trials":753,"activeCount":51},[],{"trials":755,"activeCount":51},[],{"trials":757,"activeCount":51},[],{"intervention":583,"totalTrials":47,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":761,"activeCount":51},[],{"trials":763,"activeCount":51},[],{"trials":765,"activeCount":51},[766],{"nctId":575,"briefTitle":576,"status":199,"phases":767,"completion":578,"start":501,"enrollment":6,"conditions":768,"interventions":769},[41],[22,580,581],[583,566],{"trials":771,"activeCount":51},[],{"trials":773,"activeCount":51},[],{"trials":775,"activeCount":51},[],{"intervention":777,"totalTrials":47,"cells":778},"Genexol-PM\u002FGemcitabine",{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":780,"activeCount":51},[],{"trials":782,"activeCount":51},[],{"trials":784,"activeCount":51},[785],{"nctId":786,"briefTitle":787,"status":109,"phases":788,"primaryCompletion":155,"start":789,"enrollment":790,"conditions":791,"interventions":793},"NCT01770795","A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer",[41],"2011-01",45,[792],"Non-small Cell Lung Cancer",[777],{"trials":795,"activeCount":51},[],{"trials":797,"activeCount":51},[],{"trials":799,"activeCount":51},[],{"intervention":801,"totalTrials":47,"cells":802},"Avastin\u002FFOLFIRI",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":804,"activeCount":51},[],{"trials":806,"activeCount":51},[],{"trials":808,"activeCount":51},[809],{"nctId":810,"briefTitle":811,"status":109,"phases":812,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":818},"NCT02439385","Avastin\u002FFOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis",[41],"2019-08-01","2015-08-24",44,[817],"Colorectal Cancer",[801],{"trials":820,"activeCount":51},[],{"trials":822,"activeCount":51},[],{"trials":824,"activeCount":51},[],{"intervention":558,"totalTrials":47,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":828,"activeCount":51},[],{"trials":830,"activeCount":51},[],{"trials":832,"activeCount":51},[833],{"nctId":549,"briefTitle":550,"status":109,"phases":834,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":835,"interventions":836},[41],[556],[496,558],{"trials":838,"activeCount":51},[],{"trials":840,"activeCount":51},[],{"trials":842,"activeCount":51},[],{"intervention":844,"totalTrials":47,"cells":845},"Doxorubicin\u002FGenexol-PM",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":847,"activeCount":51},[],{"trials":849,"activeCount":51},[],{"trials":851,"activeCount":51},[852],{"nctId":853,"briefTitle":854,"status":199,"phases":855,"primaryCompletion":856,"completion":857,"start":789,"enrollment":858,"conditions":859,"interventions":861},"NCT01784120","A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer",[41],"2018-01","2018-12",48,[860],"Metastatic Breast Cancer",[844],{"trials":863,"activeCount":51},[],{"trials":865,"activeCount":51},[],{"trials":867,"activeCount":51},[],{"intervention":869,"totalTrials":47,"cells":870},"Belotecan and Ifosfamide",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":872,"activeCount":51},[],{"trials":874,"activeCount":51},[],{"trials":876,"activeCount":51},[877],{"nctId":878,"briefTitle":879,"status":199,"phases":880,"primaryCompletion":881,"start":147,"enrollment":790,"conditions":882,"interventions":884},"NCT01784107","A Phase Ib\u002FII Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer",[40,41],"2018-07",[883],"Small Cell Lung Cancer",[869],{"trials":886,"activeCount":51},[],{"trials":888,"activeCount":51},[],{"trials":890,"activeCount":51},[],{"intervention":892,"totalTrials":47,"cells":893},"Gemcitabine\u002FS-1",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":895,"activeCount":51},[],{"trials":897,"activeCount":51},[],{"trials":899,"activeCount":51},[900],{"nctId":901,"briefTitle":902,"status":109,"phases":903,"primaryCompletion":202,"completion":625,"start":904,"enrollment":905,"conditions":906,"interventions":908},"NCT01929421","A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.",[41],"2009-12",36,[907],"Advanced Colorectal Cancer",[892],{"trials":910,"activeCount":51},[],{"trials":912,"activeCount":51},[],{"trials":914,"activeCount":51},[],{"intervention":916,"totalTrials":47,"cells":917},"Allergen extract",{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":919,"activeCount":51},[],{"trials":921,"activeCount":51},[922],{"nctId":923,"briefTitle":924,"status":109,"phases":925,"primaryCompletion":625,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":930},"NCT02301884","Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis",[40],"2015-03","2013-11",12,[16],[916],{"trials":932,"activeCount":51},[],{"trials":934,"activeCount":51},[],{"trials":936,"activeCount":51},[],{"trials":938,"activeCount":51},[],{"intervention":940,"totalTrials":47,"cells":941},"HollisterStier",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":957,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":943,"activeCount":51},[],{"trials":945,"activeCount":51},[946],{"nctId":947,"briefTitle":948,"status":512,"phases":949,"primaryCompletion":950,"completion":951,"start":952,"enrollment":953,"conditions":954,"interventions":955},"NCT02269566","Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients",[40],"2016-02","2016-03","2014-08",24,[16],[940,956],"Normal saline",{"trials":958,"activeCount":51},[],{"trials":960,"activeCount":51},[],{"trials":962,"activeCount":51},[],{"trials":964,"activeCount":51},[],{"intervention":966,"totalTrials":47,"cells":967},"ILIT with extract of causal allergen",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":969,"activeCount":51},[],{"trials":971,"activeCount":51},[972],{"nctId":973,"briefTitle":974,"status":109,"phases":975,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":981},"NCT02665754","Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis",[40],"2019-12","2020-01","2016-07",32,[16],[966,982,983],"ILIT with normal saline","Rescue medication for allergic rhinitis",{"trials":985,"activeCount":51},[],{"trials":987,"activeCount":51},[],{"trials":989,"activeCount":51},[],{"trials":991,"activeCount":51},[],{"intervention":982,"totalTrials":47,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":995,"activeCount":51},[],{"trials":997,"activeCount":51},[998],{"nctId":973,"briefTitle":974,"status":109,"phases":999,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":1000,"interventions":1001},[40],[16],[966,982,983],{"trials":1003,"activeCount":51},[],{"trials":1005,"activeCount":51},[],{"trials":1007,"activeCount":51},[],{"trials":1009,"activeCount":51},[],{"intervention":983,"totalTrials":47,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":51},[],{"trials":1015,"activeCount":51},[1016],{"nctId":973,"briefTitle":974,"status":109,"phases":1017,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":1018,"interventions":1019},[40],[16],[966,982,983],{"trials":1021,"activeCount":51},[],{"trials":1023,"activeCount":51},[],{"trials":1025,"activeCount":51},[],{"trials":1027,"activeCount":51},[],{"intervention":1029,"totalTrials":20,"cells":1030},"Dexmedetomidine",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1032,"activeCount":51},[],{"trials":1034,"activeCount":51},[],{"trials":1036,"activeCount":51},[],{"trials":1038,"activeCount":51},[],{"trials":1040,"activeCount":51},[],{"trials":1042,"activeCount":51},[1043,1054,1066,1076],{"nctId":1044,"briefTitle":1045,"status":1046,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":51,"conditions":1050,"interventions":1052},"NCT02966743","Effect of Sedatives on Regional Cerebral Oxygen Saturation","WITHDRAWN",[44],"2017-10","2016-11",[1051],"Cerebral Ischemia-Hypoxia",[1053,1029],"Midazolam",{"nctId":1055,"briefTitle":1056,"status":109,"phases":1057,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":318,"conditions":1061,"interventions":1063},"NCT02550795","Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer",[44],"2016-08","2016-12","2015-09",[1062],"Postoperative Nausea and Vomiting",[1029,1064,1065],"Dexmedetomidine and dexamethasone","Control",{"nctId":1067,"briefTitle":1068,"status":109,"phases":1069,"primaryCompletion":978,"completion":1058,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1074},"NCT01920542","Dexmedetomidine on Pediatric Heart Operation",[44],"2013-09",30,[1073],"Acute Renal Injury",[1029,1075],"no dexmedetomidine",{"nctId":1077,"briefTitle":1078,"status":1046,"phases":1079,"primaryCompletion":1080,"completion":1080,"start":1081,"enrollment":51,"conditions":1082,"interventions":1084},"NCT02753205","Dexmedetomidine on Optic Nerve Sheath Diameter",[44],"2018-04","2016-04",[1083],"Intracranial Hypertension",[1029,1085],"normal saline",{"intervention":956,"totalTrials":23,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1096,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1089,"activeCount":51},[],{"trials":1091,"activeCount":51},[1092],{"nctId":947,"briefTitle":948,"status":512,"phases":1093,"primaryCompletion":950,"completion":951,"start":952,"enrollment":953,"conditions":1094,"interventions":1095},[40],[16],[940,956],{"trials":1097,"activeCount":51},[],{"trials":1099,"activeCount":51},[],{"trials":1101,"activeCount":51},[],{"trials":1103,"activeCount":51},[1104,1108],{"nctId":1077,"briefTitle":1078,"status":1046,"phases":1105,"primaryCompletion":1080,"completion":1080,"start":1081,"enrollment":51,"conditions":1106,"interventions":1107},[44],[1083],[1029,1085],{"nctId":1109,"briefTitle":1110,"status":109,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":815,"conditions":1114,"interventions":1116},"NCT01464489","Intubation Time With Low Dose Rocuronium",[44],"2011-09","2011-05",[1115],"Intubation; Difficult",[1117,956],"Atropine",{"intervention":1119,"totalTrials":8,"cells":1120},"lidocaine mixed with epinephrine",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1122,"activeCount":51},[],{"trials":1124,"activeCount":51},[],{"trials":1126,"activeCount":51},[],{"trials":1128,"activeCount":51},[],{"trials":1130,"activeCount":51},[],{"trials":1132,"activeCount":51},[1133,1140],{"nctId":1134,"briefTitle":1135,"status":109,"phases":1136,"primaryCompletion":1060,"completion":1060,"start":1137,"enrollment":905,"conditions":1138,"interventions":1139},"NCT02505633","Comparison 1 Plane-1 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block",[44],"2015-07",[29],[1119],{"nctId":1141,"briefTitle":1142,"status":109,"phases":1143,"primaryCompletion":1144,"completion":1144,"start":1145,"enrollment":1146,"conditions":1147,"interventions":1148},"NCT02533557","Comparison 1 Plane-2 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block",[44],"2015-12","2015-08",70,[29],[1119],{"intervention":1065,"totalTrials":8,"cells":1150},{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1152,"activeCount":51},[],{"trials":1154,"activeCount":51},[],{"trials":1156,"activeCount":51},[],{"trials":1158,"activeCount":51},[],{"trials":1160,"activeCount":51},[],{"trials":1162,"activeCount":51},[1163,1174],{"nctId":1164,"briefTitle":1165,"status":109,"phases":1166,"primaryCompletion":1167,"completion":1167,"start":427,"enrollment":1168,"conditions":1169,"interventions":1171},"NCT01456299","Laryngeal Mask Airway (LMA) Insertion With Sevoflurane and Remifentanil",[44],"2011-12",102,[1170],"Laryngismus",[1172,1065,1173],"Remifentanil 1","Remifentanil 2",{"nctId":1055,"briefTitle":1056,"status":109,"phases":1175,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":318,"conditions":1176,"interventions":1177},[44],[1062],[1029,1064,1065],{"intervention":1172,"totalTrials":47,"cells":1179},{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1181,"activeCount":51},[],{"trials":1183,"activeCount":51},[],{"trials":1185,"activeCount":51},[],{"trials":1187,"activeCount":51},[],{"trials":1189,"activeCount":51},[],{"trials":1191,"activeCount":51},[1192],{"nctId":1164,"briefTitle":1165,"status":109,"phases":1193,"primaryCompletion":1167,"completion":1167,"start":427,"enrollment":1168,"conditions":1194,"interventions":1195},[44],[1170],[1172,1065,1173],{"intervention":1173,"totalTrials":47,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1199,"activeCount":51},[],{"trials":1201,"activeCount":51},[],{"trials":1203,"activeCount":51},[],{"trials":1205,"activeCount":51},[],{"trials":1207,"activeCount":51},[],{"trials":1209,"activeCount":51},[1210],{"nctId":1164,"briefTitle":1165,"status":109,"phases":1211,"primaryCompletion":1167,"completion":1167,"start":427,"enrollment":1168,"conditions":1212,"interventions":1213},[44],[1170],[1172,1065,1173],{"intervention":1053,"totalTrials":47,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1217,"activeCount":51},[],{"trials":1219,"activeCount":51},[],{"trials":1221,"activeCount":51},[],{"trials":1223,"activeCount":51},[],{"trials":1225,"activeCount":51},[],{"trials":1227,"activeCount":51},[1228],{"nctId":1044,"briefTitle":1045,"status":1046,"phases":1229,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":51,"conditions":1230,"interventions":1231},[44],[1051],[1053,1029],{"intervention":1233,"totalTrials":47,"cells":1234},"propofol",{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1236,"activeCount":51},[],{"trials":1238,"activeCount":51},[],{"trials":1240,"activeCount":51},[],{"trials":1242,"activeCount":51},[],{"trials":1244,"activeCount":51},[],{"trials":1246,"activeCount":51},[1247],{"nctId":1248,"briefTitle":1249,"status":109,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":293,"enrollment":472,"conditions":1252,"interventions":1253},"NCT01436799","Desflurane Versus Propofol in the Sitting Position",[44],"2011-08",[25],[1233,1254,1255,1256],"Desflurane","alfentanil","Rocuronium",{"intervention":1254,"totalTrials":47,"cells":1258},{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1263,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1260,"activeCount":51},[],{"trials":1262,"activeCount":51},[],{"trials":1264,"activeCount":51},[],{"trials":1266,"activeCount":51},[],{"trials":1268,"activeCount":51},[],{"trials":1270,"activeCount":51},[1271],{"nctId":1248,"briefTitle":1249,"status":109,"phases":1272,"primaryCompletion":1251,"completion":1251,"start":293,"enrollment":472,"conditions":1273,"interventions":1274},[44],[25],[1233,1254,1255,1256],{"intervention":1255,"totalTrials":47,"cells":1276},{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1278,"activeCount":51},[],{"trials":1280,"activeCount":51},[],{"trials":1282,"activeCount":51},[],{"trials":1284,"activeCount":51},[],{"trials":1286,"activeCount":51},[],{"trials":1288,"activeCount":51},[1289],{"nctId":1248,"briefTitle":1249,"status":109,"phases":1290,"primaryCompletion":1251,"completion":1251,"start":293,"enrollment":472,"conditions":1291,"interventions":1292},[44],[25],[1233,1254,1255,1256],{"intervention":1256,"totalTrials":47,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1296,"activeCount":51},[],{"trials":1298,"activeCount":51},[],{"trials":1300,"activeCount":51},[],{"trials":1302,"activeCount":51},[],{"trials":1304,"activeCount":51},[],{"trials":1306,"activeCount":51},[1307],{"nctId":1248,"briefTitle":1249,"status":109,"phases":1308,"primaryCompletion":1251,"completion":1251,"start":293,"enrollment":472,"conditions":1309,"interventions":1310},[44],[25],[1233,1254,1255,1256],{"intervention":1064,"totalTrials":47,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1314,"activeCount":51},[],{"trials":1316,"activeCount":51},[],{"trials":1318,"activeCount":51},[],{"trials":1320,"activeCount":51},[],{"trials":1322,"activeCount":51},[],{"trials":1324,"activeCount":51},[1325],{"nctId":1055,"briefTitle":1056,"status":109,"phases":1326,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":318,"conditions":1327,"interventions":1328},[44],[1062],[1029,1064,1065],{"intervention":1330,"totalTrials":47,"cells":1331},"propofol concentration",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1333,"activeCount":51},[],{"trials":1335,"activeCount":51},[],{"trials":1337,"activeCount":51},[],{"trials":1339,"activeCount":51},[],{"trials":1341,"activeCount":51},[],{"trials":1343,"activeCount":51},[1344],{"nctId":1345,"briefTitle":1346,"status":109,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":472,"conditions":1350,"interventions":1352},"NCT02268656","Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction With a Single-dose Dexmedetomidine",[44],"2015-02","2014-10",[1351],"Igel",[1330],{"intervention":1354,"totalTrials":47,"cells":1355},"Iloprost",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1357,"activeCount":51},[],{"trials":1359,"activeCount":51},[],{"trials":1361,"activeCount":51},[],{"trials":1363,"activeCount":51},[],{"trials":1365,"activeCount":51},[],{"trials":1367,"activeCount":51},[1368],{"nctId":1369,"briefTitle":1370,"status":109,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1377},"NCT01054105","Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension",[],"2018-12-25","2010-10",73,[1376],"Pulmonary Arterial Hypertension",[1354],{"intervention":1379,"totalTrials":47,"cells":1380},"statins",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1382,"activeCount":51},[],{"trials":1384,"activeCount":51},[],{"trials":1386,"activeCount":51},[],{"trials":1388,"activeCount":51},[],{"trials":1390,"activeCount":51},[],{"trials":1392,"activeCount":51},[1393],{"nctId":1394,"briefTitle":1395,"status":109,"phases":1396,"completion":1397,"start":1398,"conditions":1399,"interventions":1400},"NCT00546559","Differential Metabolic Effects of Statins",[],"2008-03","2004-01",[13],[1379],{"intervention":1402,"totalTrials":47,"cells":1403},"pravastatin, rosuvastatin",{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1405,"activeCount":51},[],{"trials":1407,"activeCount":51},[],{"trials":1409,"activeCount":51},[],{"trials":1411,"activeCount":51},[],{"trials":1413,"activeCount":51},[],{"trials":1415,"activeCount":51},[1416],{"nctId":1417,"briefTitle":1418,"status":109,"phases":1419,"primaryCompletion":1420,"completion":1421,"start":904,"conditions":1422,"interventions":1423},"NCT01011127","Different Metabolic Effects of Statins",[],"2010-07","2010-08",[13],[1402],{"intervention":1425,"totalTrials":47,"cells":1426},"Aprepitant",{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1428,"activeCount":51},[],{"trials":1430,"activeCount":51},[],{"trials":1432,"activeCount":51},[],{"trials":1434,"activeCount":51},[],{"trials":1436,"activeCount":51},[],{"trials":1438,"activeCount":51},[1439],{"nctId":1440,"briefTitle":1441,"status":109,"phases":1442,"primaryCompletion":316,"completion":316,"start":1443,"enrollment":318,"conditions":1444,"interventions":1445},"NCT01440673","Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy",[44],"2010-03",[1062],[1425],{"intervention":1447,"totalTrials":47,"cells":1448},"Magnesium Sulfate, Injectable",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1450,"activeCount":51},[],{"trials":1452,"activeCount":51},[],{"trials":1454,"activeCount":51},[],{"trials":1456,"activeCount":51},[],{"trials":1458,"activeCount":51},[],{"trials":1460,"activeCount":51},[1461],{"nctId":1462,"briefTitle":1463,"status":199,"phases":1464,"primaryCompletion":1465,"completion":1466,"start":1059,"enrollment":1467,"conditions":1468,"interventions":1470},"NCT03020706","Effect of Magnesium Sulphate on Neostigmine",[44],"2017-01","2017-12",166,[1469],"Neuromuscular Blockade",[1447],{"intervention":1075,"totalTrials":47,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1474,"activeCount":51},[],{"trials":1476,"activeCount":51},[],{"trials":1478,"activeCount":51},[],{"trials":1480,"activeCount":51},[],{"trials":1482,"activeCount":51},[],{"trials":1484,"activeCount":51},[1485],{"nctId":1067,"briefTitle":1068,"status":109,"phases":1486,"primaryCompletion":978,"completion":1058,"start":1070,"enrollment":1071,"conditions":1487,"interventions":1488},[44],[1073],[1029,1075],{"intervention":1490,"totalTrials":47,"cells":1491},"Sibutramine",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":51},[],{"trials":1495,"activeCount":51},[],{"trials":1497,"activeCount":51},[],{"trials":1499,"activeCount":51},[],{"trials":1501,"activeCount":51},[],{"trials":1503,"activeCount":51},[1504],{"nctId":1505,"briefTitle":1506,"status":109,"phases":1507,"primaryCompletion":1420,"completion":1420,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1512},"NCT01184560","Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine",[44],"2010-02",174,[1511],"Obesity",[1490,1513],"Orlistat",{"intervention":1513,"totalTrials":47,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1517,"activeCount":51},[],{"trials":1519,"activeCount":51},[],{"trials":1521,"activeCount":51},[],{"trials":1523,"activeCount":51},[],{"trials":1525,"activeCount":51},[],{"trials":1527,"activeCount":51},[1528],{"nctId":1505,"briefTitle":1506,"status":109,"phases":1529,"primaryCompletion":1420,"completion":1420,"start":1508,"enrollment":1509,"conditions":1530,"interventions":1531},[44],[1511],[1490,1513],{"intervention":1117,"totalTrials":47,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1535,"activeCount":51},[],{"trials":1537,"activeCount":51},[],{"trials":1539,"activeCount":51},[],{"trials":1541,"activeCount":51},[],{"trials":1543,"activeCount":51},[],{"trials":1545,"activeCount":51},[1546],{"nctId":1109,"briefTitle":1110,"status":109,"phases":1547,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":815,"conditions":1548,"interventions":1549},[44],[1115],[1117,956],{"intervention":1551,"totalTrials":47,"cells":1552},"concomitant intranasal antihistamine and corticosteroid",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1554,"activeCount":51},[],{"trials":1556,"activeCount":51},[],{"trials":1558,"activeCount":51},[],{"trials":1560,"activeCount":51},[],{"trials":1562,"activeCount":51},[],{"trials":1564,"activeCount":51},[1565],{"nctId":1566,"briefTitle":1567,"status":199,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1573},"NCT05708157","Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis",[],"2024-02-29","2023-01-17",240,[16],[1551]]